Multiple Myeloma
From the Journals
Similar results for once- or twice-weekly carfilzomib in MM
There was no significant difference in safety or survival outcomes among patients with newly diagnosed multiple myeloma.
News
FDA approves daratumumab split-dosing regimen in MM
The split-dose regimen resulted in a similar rate of infusion site reactions.
From the Journals
Trial supports less aggressive myeloma treatment
A less intensive transplant and maintenance strategy proved equally effective as more aggressive approaches in patients with multiple myeloma.
From the Journals
AML, myeloma risk higher for breast cancer survivors
Risk for both myeloid and lymphoid neoplasms was higher among breast cancer survivors than in the general population.
From the Journals
With RRMM and renal impairment, carfilzomib improves survival
In a subgroup analysis from ENDEAVOR, progression-free survival was more than doubled, compared with bortezomib.
Conference Coverage
Next-generation anti-BCMA CAR T shows promise for RRMM
SAN DIEGO – CAR T cells have been detectable up to 9 months after infusion.
News
Group proposes new grading systems for CRS, neurotoxicity
A group of experts has proposed new consensus definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity related to...
News
EC approves split dosing regimen for daratumumab
The European Commission (EC) has granted marketing authorization for a split dosing regimen for daratumumab (Darzalex®). The approval provides...
News
DRd improves PFS in transplant-ineligible MM
SAN DIEGO—An interim analysis from the MAIA trial showed that adding daratumumab to lenalidomide and dexamethasone could significantly improve...
Conference Coverage
Frailty-adjusted treatment strategy emerges in myeloma
SAN DIEGO – The trial found that lenalidomide/dexamethasone with lenalidomide maintenance led to longer event-free survival.
News
Health Canada approves new indication for daratumumab
Health Canada has approved a third indication for daratumumab (Darzalex®) in multiple myeloma (MM). The drug is now approved for use in...